Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Ronald Stam

Principal Investigator
Ronald Stam
Ronald Stam
Since 2016, Dr. Ronald Stam leads a research group in the Princess Máxima Center. His team studies high risk forms of leukemia. By examining the genetic profile, Stam aims to discover new therapeutic targets.
Phone +31 (0) 88 972 76 72

Ronald Stam was born on December 9th 1974 in Vlaardingen, The Netherlands. After obtaining his bachelors degree in Biochemistry (Hoger Laboratorium Onderwijs, Delft, The Netherlands) and his masters degree in Molecular Biology (Leiden University, Leiden, The Netherlands), Ronald accepted his PhD for his research on MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants in 2006 at the Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands. Subsequently, Ronald was appointed research group leader in the laboratory of prof. dr. Rob Pieters at the Erasmus MC – Sophia Children’s Hospital, until 2016. In September 2016, Ronald accepted the position of Principal Investigator at the Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands. With his enthusiastic research group, currently consisting of two post-docs, four PhD-students, and two skilful technicians, Ronald continues his work on MLL-rearranged infant ALL as well as on other high-risk types of childhood acute leukemia.

In 2005, Ronald received the Basic Science Award at the 34th annual SIOP (International Society of Pediatric Oncology) meeting, Vancouver, Canada. In 2010 Ronald received an award for groundbreaking research in pediatric oncology from KIKA (Stichting Kinderen Kanker vrij) the Netherlands.

  • A CRISPR/Cas9 engineered Mpl<sup>S504N</sup> mouse model recapitulates human myelofibrosis

    • okt. 2022
    • Fabienne R.S., Adriaanse, et al
    • Leukemia
  • Editorial

    • aug. 2022
    • Maria Teresa, Esposito, et al
    • Frontiers in Pharmacology
  • Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells

    • apr. 2022
    • Vivian, Morris, et al
    • Cell Reports
  • High-Throughput Drug Library Screening in Primary KMT2A-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling

    • mrt. 2022
    • Priscilla, Wander, et al
    • Biomedicines
  • Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics

    • jan. 2022
    • Tito, Candelli, et al
    • Leukemia
View all publications